Immunome

IMNMPhase 3

Immunome is a clinical-stage biotech dedicated to improving outcomes for cancer patients through a portfolio of targeted therapies, primarily centered on antibody-drug conjugates (ADCs). The company's most advanced asset is varegacestat, a gamma secretase inhibitor in Phase 3 for desmoid tumors, complemented by earlier-stage ADC and radioligand programs. Under the leadership of CEO Clay Siegall, co-founder of Seagen, Immunome leverages significant ADC expertise to pursue differentiated targets and optimize therapeutic candidates for efficacy and tolerability.

Market Cap

$2.3B

Focus

Biologics

IMNM · Stock Price

USD 20.01+15.19 (+315.15%)

Historical price data

AI Company Overview

Technology Platform

A holistic, data-driven platform for the discovery and optimization of antibody-drug conjugates (ADCs) and radioligand therapies, systematically engineering the antibody, linker, and payload components for efficacy, tolerability, and clinical differentiation.

Pipeline Snapshot

7 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
AL102	Desmoid	Phase 2/3
varegacestat + Itraconazole (200 mg)	Healthy Volunteer	Phase 1
varegacestat	Healthy Volunteer	Phase 1
IM-1021	Solid Malignancies	Phase 1
varegacestat	Healthy Volunteer	Phase 1

Funding History

Total raised: $125M

PIPE$125MUndisclosedJan 1, 2023

IPOUndisclosedUndisclosedNov 1, 2020

Opportunities

Near-term catalyst from Phase 3 data in desmoid tumors; expansion of the clinical pipeline with IM-1021 and IM-3050 data readouts; leveraging the ADC platform to generate new preclinical candidates for pipeline expansion and potential partnerships; potential to apply expertise to in-license or acquire additional targeted oncology assets.

Risk Factors

High dependency on the success of the lead asset, varegacestat, in Phase 3; intense competition in the ADC field from larger, well-funded players; inherent risks of clinical failure for all earlier-stage programs; execution risk in managing a growing clinical portfolio simultaneously.

Competitive Landscape

Faces competition in desmoid tumors (e.g., other GSIs, TKIs), in the ROR1 ADC space (e.g., Merck/VelosBio), and in FAP-targeted therapies. Differentiation is claimed through optimized ADC design (e.g., IM-1021's DAR=8 and proprietary payload) and the unique experience of its leadership team in successfully developing and commercializing multiple ADCs.

Publications

Patents

Pipeline